{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-25-000212","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.178595+00:00","generated_at":"2026-05-26T08:06:21.121335+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunic's IMU-856 shows dose-dependent GLP-1 increase in celiac trial; preclinical weight loss","bullets":["Post-hoc phase 1b analysis: dose-dependent GLP-1 increase up to 250% vs placebo; p=0.014 (80mg) and p=0.003 (160mg).","Preclinical 6-month study: IMU-856 reduced body weight gain and food consumption up to -40% vs control in a dose-dependent manner.","Program is Phase 2 ready; company plans to explore IMU-856 as oral treatment for obesity (market >$170B by 2031).","Data also presented at ECCO 2025 digital oral presentation; webcast held Feb 20, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-25-000212","json":"https://secwatch.observer/filing/0001193805-25-000212.json","markdown":"https://secwatch.observer/filing/0001193805-25-000212.md","text":"https://secwatch.observer/filing/0001193805-25-000212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000212/0001193805-25-000212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000212/e664213_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T08:06:21.121335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}